Scilex Pharmaceuticals Inc. co-founder Anthony Mack was found liable for breaching a restrictive covenant agreement he entered into with Sorrento Therapeutics Inc. at the time he engineered the sale of a controlling stake in Scilex to Sorrento.
Scilex and Sorrento are biopharmaceutical companies that develop pain management products, among others.
Mack signed a non-competition agreement pledging not to engage in activities that compete with the Scilex product, the ZTlido lidocaine patch, and agreed to stay on after the sale as Scilex’s president.
After the transaction, Sorento and Scilex alleged, Mack began developing a new pharmaceutical business, Virpax Pharmaceuticals Inc., also ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.